Explore the words cloud of the LYMPHOSIGN project. It provides you a very rough idea of what is the project "LYMPHOSIGN" about.
The following table provides information about the project.
Coordinator |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Organization address contact info |
Coordinator Country | France [FR] |
Project website | https://www.up2europe.eu/european/projects/integrated-study-of-the-role-of-b-cell-receptor-signaling-in-the-development-of-follicular-lymphoma_33102.html |
Total cost | 200˙119 € |
EC max contribution | 200˙119 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2014 |
Funding Scheme | MSCA-IF-GF |
Starting year | 2015 |
Duration (year-month-day) | from 2015-12-01 to 2018-10-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | FR (PARIS) | coordinator | 200˙119.00 |
2 | United States Department of Health and Human Services | US (Washington D.C.) | partner | 0.00 |
'Signaling through the B cell receptor (BCR) is central to the development and maintenance of B cells. In light of the numerous proliferative and survival pathways activated downstream of the BCR, it comes as no surprise that malignant B cells would co-opt this receptor to promote their own growth and survival. However, direct evidence for BCR signaling in human lymphoma has only come to light recently. In this proposal, I aim to better understand the role for antigen-dependent vs. antigen-dependent BCR signaling as a pathogenic mechanism in the progression of Follicular lymphoma (FL), a indolent lymphoid malignancy that retain BCR expression during malignant progression. Further investigating the intrinsic role of BCR might lead to the development of new therapeutic approaches based on the inhibition of the BCR pathways. Using an innovative loss-of -function RNA interference genetic screen together with an engineered in vitro system allowing to test FL patients's BCR reactivity and identify putative ligands, we will 1) determine whether BCR signalling in FL relies to 'chronic active' or 'tonic' signals and 2) identify the nature of antigen(s) recognized by FL's BCR that may sustain signalling; each signalling pathway offering different opportunities for therapeutic intervention. For this project, I decided to chose the Louis Staudt’s group at the National Cancer Institute (NIH) for the outgoing phase since his group has been looking for years how to target B-cell receptor signaling as a treatment strategy. The unique expertise in the state-of the art functional genomic methodologies acquired during my stay at the NCI will be crucial for setting-up new scientific projects, promote extended collaborations and strongly support my re-establishement in Europe to reach an independent position. '
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Roland Schmitz, George W. Wright, Da Wei Huang, Calvin A. Johnson, James D. Phelan, James Q. Wang, Sandrine Roulland, Monica Kasbekar, Ryan M. Young, Arthur L. Shaffer, Daniel J. Hodson, Wenming Xiao, Xin Yu, Yandan Yang, Hong Zhao, Weihong Xu, Xuelu Liu, Bin Zhou, Wei Du, Wing C. Chan, Elaine S. Jaffe, Randy D. Gascoyne, Joseph M. Connors, Elias Campo, Armando Lopez-Guillermo, Andreas Rosenwald, Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma published pages: 1396-1407, ISSN: 0028-4793, DOI: 10.1056/nejmoa1801445 |
New England Journal of Medicine 378/15 | 2019-10-29 |
2018 |
James D. Phelan, Ryan M. Young, Daniel E. Webster, Sandrine Roulland, George W. Wright, Monica Kasbekar, Arthur L. Shaffer, Michele Ceribelli, James Q. Wang, Roland Schmitz, Masao Nakagawa, Emmanuel Bachy, Da Wei Huang, Yanlong Ji, Lu Chen, Yandan Yang, Hong Zhao, Xin Yu, Weihong Xu, Maryknoll M. Palisoc, Racquel R. Valadez, Theresa Davies-Hill, Wyndham H. Wilson, Wing C. Chan, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Andreas Rosenwald, German Ott, Jan Delabie, Lisa M. Rimsza, Fausto J. Rodriguez, Fayez Estephan, Matthias Holdhoff, Michael J. Kruhlak, Stephen M. Hewitt, Craig J. Thomas, Stefania Pittaluga, Thomas Oellerich, Louis M. Staudt A multiprotein supercomplex controlling oncogenic signalling in lymphoma published pages: 387-391, ISSN: 0028-0836, DOI: 10.1038/s41586-018-0290-0 |
Nature 560/7718 | 2019-04-02 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LYMPHOSIGN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LYMPHOSIGN" are provided by the European Opendata Portal: CORDIS opendata.